A Form 4 filed with the SEC on September 16, 2026, discloses that David Raymond Stewart, a director of AAON, Inc. (NASDAQ:AAON), purchased 1,000 shares of common stock on September 15, 2026, at a price of $74.66 per share.
Director Zachary W. Bawel filed a Form 4 with the SEC on September 16, 2026, disclosing a purchase of common stock in German American Bancorp, Inc. (NASDAQ:GABC) on September 15, 2026, through the company's Dividend Reinvestment and Stock Purchase Plan.
A Form 4 filed on September 16, 2026 reports that Christina M. Ryan, a director of German American Bancorp, Inc. (NASDAQ:GABC), acquired 124.2654 shares of common stock on September 15, 2026 through the company's Dividend Reinvestment and Stock Purchase Plan.
David Kirn, President and Chief Executive Officer of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), filed a Form 4 on September 16, 2026, disclosing the sale of 58,333 shares of common stock on September 14, 2026.
John L. Brottem, General Counsel of Alamar Biosciences, Inc. (NASDAQ:ALMR), filed a Form 4 on September 16, 2026, reporting the acquisition of 29,000 restricted stock units and an employee stock option covering 85,000 shares of common stock, both transacted on September 14, 2026.
Johanna Mercier, Chief Commercial and Corporate Affairs Officer at Gilead Sciences, Inc. (NASDAQ:GILD), filed a Form 4 on September 16, 2026, disclosing the sale of 3,000 shares of common stock on September 15, 2026, pursuant to a Rule 10b5-1 trading plan.
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., filed a Form 4 on September 16, 2026, reporting the sale of 3,000 shares of Gilead common stock on September 15, 2026.
Stride, Inc. (NYSE:LRN) Executive Vice President and General Counsel Greerson Greene McMullen filed a statement of changes in beneficial ownership on September 16, 2026, disclosing a share disposition on September 15, 2026.
A Form 4 filed on September 16, 2026 with the U.S. Securities and Exchange Commission reported that James L. Robo, a director of Kayne Anderson BDC, Inc. (NYSE:KBDC), acquired a total of 400,000 shares of common stock through two purchases on September 14 and …
Director James N. Wilson filed a Form 4 with the SEC on September 16, 2026, reporting the sale of 10,000 shares of Corcept Therapeutics Inc common stock on September 15, 2026, executed under a pre-established 10b5-1 trading plan.